Wedbush Reiterates Neutral on Design Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico reiterated a Neutral rating on Design Therapeutics (NASDAQ:DSGN) and maintained a $5 price target.

March 20, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico reiterated a Neutral rating on Design Therapeutics and maintained a $5 price target.
The reiteration of a Neutral rating and maintenance of a $5 price target by Wedbush analyst Laura Chico suggests that there are no immediate catalysts expected to significantly change the stock's valuation in the short term. The neutral stance indicates a balanced view on the stock's prospects, neither overly bullish nor bearish.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100